Sanofi Gains China NMPA Nod For Myqorzo And Redemplo In OHCM And FCS Treatments

Sanofi announced NMPA approval in China for Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy and Redemplo (plozasiran) for lowering triglycerides in adults with familial chylomicronaemia syndrome, and in August 2025 acquired Greater China rights to Redemplo from Visirna/Arrowhead. Myqorzo is a selective cardiac myosin inhibitor and Redemplo is an siRNA targeting apoc-III, representing targeted therapies for rare cardiovascular and lipid disorders with potential commercial upside in China. The stock reaction was mixed: SNY closed Jan 14 at $47.89 (+1.46%) but fell in overnight trading to $45.72 (-4.53%), indicating short-term volatility despite the regulatory wins.

Analysis

Market structure: Sanofi (SNY) is the primary beneficiary—China approval for Myqorzo (aficamten) and Redemplo (plozasiran) opens a controlled rare-disease pricing channel with likely high ASPs but small patient populations; Arrowhead/Visirna (ARWR exposure) gets near-term non-dilutive license consideration and milestone upside. Competitive dynamics: Myqorzo directly competes with mavacamten (BMY) in oHCM, suggesting share contests in cardiology centers of excellence and potential price concessions; apolipoprotein‑CIII siRNA faces incumbent therapies and will rely on differentiated safety/efficacy to win limited formulary slots. Supply/demand: demand is predictable but tiny—peak China revenues likely in the low‑hundreds of millions annually for each drug rather than billions, so capacity and launch execution matter more than unit economics. Cross-asset: expect transient equity IV spikes and spread widening in credit for smaller biotech partners; limited macro FX/commodity impact, modest positive for SNY credit curve if launches ramp and reduce future R&D pressure.

Risk assessment: Tail risks include post‑market safety signals (1–5% chance materially denting uptake), failed NRDL listing or unfavorable reimbursement (30–40% chance delaying mass access), and patent/legal contests from incumbents. Time horizons: immediate (days) volatility around press and aftermarket moves; short term (weeks–6 months) driven by tender, hospital procurement, and physician uptake metrics; long term (12–36 months) driven by reimbursement, real‑world effectiveness and peak sales ramp. Hidden dependencies: success hinges on Chinese formulary negotiations, local manufacturing/CMC scale, and cardiology/rare disease KOL adoption—not raw approval alone. Catalysts to watch: first 30‑90 day hospital procurement reports, NRDL negotiations (6–12 months), and any competitor label updates or litigation filings.

Trade implications: Direct play—establish a measured 2–3% long SNY equity position on a pullback to $44–$46, target $50–$53 in 3–9 months, stop‑loss 8% below entry; alternatively use a 90‑day 47.5/52.5 call spread to cap downside. Pair trade—long SNY (2%) vs short BMY (1.5%) to express share capture risk in oHCM; add if BMY outperforms without new data. Short ARWR small (0.5–1%) on the assumption that Visirna milestone upside is capped and sentiment may reprice after licensing recognition; size conservatively and use 6% stop. Sector rotation: trim speculative small‑cap RNA exposure and shift 3–5% into large-cap diversified pharma with China commercialization capability (SNY, some BMY hedge).

Contrarian angles: Consensus overweights headline approval as immediate revenue; market likely underestimates reimbursement lag and the small addressable population—this suggests the overnight SNY pullback (-4.5%) is an overreaction to timing uncertainty and creates a tactical buy window if fundamentals hold. Historical parallels: prior China rare‑disease approvals often required 6–12 months of local listing/tender before meaningful sales—binary outcomes then drive 20–40% re‑ratings. Unintended consequences include pricing pressure on mavacamten leading to class discounting, and manufacturing/CMC issues for siRNA that could cap unit supply. Action trigger: if NRDL inclusion occurs within 12 months, re‑rate SNY to add exposure; if no listing after 12 months, cut exposure by half.

Key Decisions for Investors

• Establish a 2–3% long position in SNY on weakness to $44–$46; target $50–$53 in 3–9 months and employ an 8% stop‑loss to limit event risk tied to Chinese reimbursement outcomes.
• If preferring defined risk, buy a 90‑day SNY 47.5/52.5 call spread sized to equal a 2% position; exit if spread value declines 50% or SNY exceeds 52.5 before expiration.
• Initiate a pair trade: long SNY (2%) vs short BMY (1.5%) to capture potential share shift in oHCM; close the pair if SNY underperforms by >7% relative to BMY in 60 days or after NRDL decision.
• Small tactical short of ARWR (0.5–1%) on the thesis that Visirna licensing upside is limited and sentiment is fragile; enter only if ARWR rallies >8% on news, with a 6% stop‑loss and max hold 6 months.
• Monitor three specific catalysts: (1) China NRDL negotiation status within 6–12 months (add 1–2% SNY if listed), (2) first 30‑90 day hospital procurement/units sold for Redemplo/Myqorzo (if >50 hospitals report purchases within 90 days, add exposure), and (3) any NMPA/post‑market safety notices (exit or trim 50% if serious safety signal emerges).